Solventum (SOLV) FY2025 10-K Annual Report
Solventum (SOLV) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 27, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Solventum FY2025 10-K Analysis
Business Overview
- • Global healthcare company (~20,000 employees, ~$0 revenue figures disclosed) across three segments: MedSurg 57.9%, Health Information Systems 16.3%, Dental Solutions 16.2% of 2025 sales
- • Two major portfolio moves in 2025: acquired Acera Surgical (bioscience, adds synthetic tissue matrices) and divested Purification & Filtration business to Thermo Fisher Scientific
Management Discussion & Analysis
- • Revenue $8,325M, up 0.9% YoY ($71M increase); organic growth 3.3%, offset by -3.0% divestiture impact from Purification & Filtration sale
- • Operating margin 26.2% vs 12.6% in 2024 (includes $1.5B gain on P&F sale); SG&A 37.0% vs 33.7%; R&D 8.9% vs 9.4%
Risk Factors
- • 3M sole-source supplier for materials tied to ~$3B revenue (FY2025); ~$2B from proprietary material with no identified substitute or internal manufacturing capability
- • $5B outstanding debt post-spin as of Dec 31, 2025; constrains capital allocation, raises downgrade risk, and limits strategic flexibility
Solventum FY2025 Key Financial MetricsXBRL
Revenue
$8.3B
▲ +0.9% YoY
Net Income
$1.6B
▲ +224.8% YoY
Gross Margin
53.5%
▼ -218bp YoY
Operating Margin
26.2%
▲ +1365bp YoY
Net Margin
18.7%
▲ +1289bp YoY
ROE
30.8%
▲ +1463bp YoY
Total Assets
$14.3B
▼ -1.1% YoY
EPS (Diluted)
$8.88
▲ +221.7% YoY
Operating Cash Flow
$369M
▼ -68.9% YoY
Source: XBRL data from Solventum FY2025 10-K filing on SEC EDGAR. All figures in USD.
Other Solventum Annual Reports
Get deeper insights on Solventum
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.